InsiderTrades

Form 4/A for UTHR UNITED THERAPEUTICS Corp

Accepted 2022-07-11 00:00:00 ET · period of report 2022-07-08 · accession 0001415889-22-007627 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DA 2022-07-11 2022-07-08 UTHR KURZWEIL RAY Dir M - OptEx $0.00 +1,080 10.3K +12% $0
DA 2022-07-11 2022-07-08 UTHR KURZWEIL RAY Dir M - OptEx $0.00 -1,080 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-07-08 M A 1,080 $0.00 10,300 D — — (F1) This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock). (F2) Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.
2 Derivative Restricted Stock Unit 2022-07-08 M D 1,080 $0.00 0 D $0.00 · 2022-07-08 to — 1,080 Common Stock (F1) This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock). (F3) Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. (F4) Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.